RLAY vs TARS: stock comparison and AI forecast
Relay Therapeutics, Inc. (RLAY) and Tarsus Pharmaceuticals, Inc. (TARS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
RLAY Relay Therapeutics, Inc.
- Price
- $18.60 +48.7% · 6M
- Market Cap
- $4.08B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
TARS Tarsus Pharmaceuticals, Inc.
- Price
- $67.52 +5.6% · 6M
- Market Cap
- $3.33B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- RLAY is 1.2 times larger than TARS by market capitalization ($4.08B against $3.33B).
- Over the last six months RLAY returned +48.7% and TARS +5.6%.
- TARS turns -102.9% of its revenue into net income, against -2837.0% for RLAY.
- TARS carries 3.86 times debt per unit of equity, against 0.10 times for RLAY.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | RLAY | TARS |
|---|---|---|
| Market Cap | $4.08B | $3.33B |
| P/B Ratio | 4.98x | 32.01x |
| EPS | $-1.55 | $-15.64 |
| Book Value/Share | $3.74 | $2.11 |
| Revenue/Share | $0.05 | $13.83 |
| FCF/Share | – | $0.66 |
Profitability & Margins
| Metric | RLAY | TARS |
|---|---|---|
| ROE | -35.9% | -675.0% |
| ROA | -32.6% | -138.9% |
| ROIC | -38.0% | – |
| Operating Margin | -3094.6% | -102.0% |
| Net Margin | -2837.0% | -102.9% |
| EBT Margin | -3094.6% | -97.2% |
| Tax Rate | – | -1.8% |
Financial Health
| Metric | RLAY | TARS |
|---|---|---|
| Current Ratio | 14.62x | 1.96x |
| Quick Ratio | – | 1.94x |
| D/E Ratio | 0.10x | 3.86x |
| Financial Leverage | 1.10x | 4.86x |
| Interest Coverage | – | -303.0x |
| Working Capital | $806M | $218M |
Cash Flow
| Metric | RLAY | TARS |
|---|---|---|
| Operating Cash Flow | -$214M | $50M |
| Free Cash Flow | – | $32M |
| Capital Spending | – | -$17M |
| FCF/Sales | – | 4.8% |
| CapEx/Sales | – | 2.6% |
Operational Efficiency
| Metric | RLAY | TARS |
|---|---|---|
| Asset Turnover | 0.01x | 1.35x |
| Receivables Turnover | – | 6.8x |
| Fixed Assets Turnover | 17.8x | 32.9x |
| Days Sales Outstanding | – | 54 days |
Income Statement
| Metric | RLAY | TARS |
|---|---|---|
| Total Revenue | $10M | $682M |
| Operating Income | -$320M | -$696M |
| Net Income | -$294M | -$702M |
| R&D Expense | $280M | $116M |
| SG&A Expense | – | $586M |
Dividend & Shareholder Information
| Metric | RLAY | TARS |
|---|---|---|
| Shares Outstanding | 219M | 49M |
RLAY vs TARS: stock comparison and AI forecast
Which is bigger, RLAY or TARS?
RLAY is 1.2 times larger than TARS by market capitalization ($4.08B against $3.33B).
Which stock performed better over the last six months, RLAY or TARS?
Over the last six months RLAY returned +48.7% and TARS +5.6%.
Which one does Intratio's AI model rank higher, RLAY or TARS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.